Effects of different doses of oral cholecalciferol on serum 25(OH)D, PTH, calcium and bone markers during fall and winter in schoolchildren

Ghazi, Ali A.; Hosseinpanah, Farhad; Ardakani, Emad M.; Ghazi, Siavash; Hedayati, Mehdi; Azizi, Fereidoun

doi:10.1038/ejcn.2010.169

Cited by 42 publications

(43 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two studies were from Iran [27, 28], one study from Lebanon [24] and one study from Israel [26]. The four studies were conducted in healthy school children, girls and boys, and the range of mean age of participants was 9.8–16.6 years.…”

Section: Resultsmentioning

confidence: 99%

“…The baseline mean 25(OH)D level ranged between 7.9 and 25 ng/ml (Table 1, Appendix 2). The vitamin D assay used was high pressure liquid chromatography (HPLC) in one study [28], and immune-assays were used in the other three [24, 26, 27]. Concomitant calcium supplementation was administered in one study [28].…”

Section: Resultsmentioning

confidence: 99%

“…Compliance with vitamin D supplementation was described in one study only, ranging between 97–98% in the low, intermediate, and placebo arms [24]. The reported rates of loss to follow up were less than 15% in three studies [24, 27, 28], and no loss to follow up was reported in one study [26]. The risk of bias assessed by the Cochrane Tool was judged as high in the trial by Neyestani et al (mostly related to inadequate allocation concealment and performance bias) [28], unclear in the trials by Ghazi et al [27] and Mayan et al [26], and low in the trial by El Hajj Fuleihan et al [24, 25], respectively (Figure 2A, Appendix 3A).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Vitamin D replacement in children, adolescents and pregnant women in the Middle East and North Africa

et al. 2017

View full text Add to dashboard Cite

Introduction Hypovitaminosis D affects one-third to two-thirds of children and pregnant women from the Middle East and North Africa (MENA) region. Objective To evaluate in infants, children, adolescents and pregnant women, from the MENA region, the effect of supplementation with different vitamin D doses on the change in 25-hydroxyvitamin D [25(OH)D] level reached, and other skeletal and non-skeletal outcomes. Methods This is a systematic review of randomized controlled trials of vitamin D supplementation conducted in the MENA region. We conducted a comprehensive literature search in 7 databases, without language or time restriction, until November 2016. Two reviewers abstracted data from the included studies, independently and in duplicate. We calculated the mean difference (MD) and 95% CI of 25(OH)D level reached when at least 2 studies were eligible in each comparison (low (< 800 IU), intermediate (800–2,000 IU) or high (> 2,000 IU) daily dose of vitamin D, or placebo). We pooled data using RevMan version 5.3. Results We identified a total of 15 eligible trials: one in infants, 4 in children and adolescents and 10 in pregnant women. In children and adolescents, an intermediate vitamin D dose (1,901 IU/d), resulted in a mean difference in 25(OH)D level of 13.5 (95% Confidence Interval (CI) 8.1;18.8) ng/ml, compared to placebo, favoring the intermediate dose (p < 0.001). The proportion of children and adolescents reaching a 25(OH)D level ≥ 20 ng/ml was 74% in the intermediate dose group. In pregnant women, four trials started supplementation at 12–16 weeks of gestation and continued until delivery, and six trials started supplementation at 20–28 weeks gestation and stopped it at delivery. The MD in 25(OH)D level reached was 8.6 (95% CI 5.3–11.9) ng/ml (p <0.001) comparing the high dose (3,662 IU/d) to the intermediate dose (1,836 IU/d), and 12.3 (95% CI 6.4–18.2) ng/ml (p <0.001), comparing the high dose (3,399 IU/d) to the low dose (375 IU/d). Comparing the intermediate (1,832 IU/d) to the low dose (301 IU/d), the MD in 25(OH)D level achieved was 7.8 (95% CI 4.5–10.8) ng/ml (p < 0.001). The proportion of pregnant women reaching a 25(OH)D level ≥ 20 ng/ml was 80–90%, 73% and 27–43% in the high, intermediate, and low dose groups, respectively. The risk of bias in the included studies, for children, adolescents and pregnant women, ranged from low to high. Conclusion In children, adolescents and pregnant women from the MENA, an intermediate vitamin D dose of 1,000–2,000 IU seems necessary to allow for the majority of the population to reach a desirable 25(OH)D level of 20 ng/ml. Further high quality RCTs are required to confirm/refute the beneficial impact of vitamin D supplementation on various clinically important outcomes.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D replacement in children, adolescents and pregnant women in the Middle East and North Africa

et al. 2017

View full text Add to dashboard Cite

show abstract

“…71,72 Current uK and north american recommendations for oral vitamin D 3 dosing (200-400 iu per day) 73,74 have been shown to be ineffective at raising serum vitamin D concentrations in children with vitamin D insufficiency, whereas doses of 1,000-2,000 iu per day were both effectiv e and safe in pediatric populations. 67,75 First-line management of MS in children acute demyelinating attacks are typically managed with corticosteroids. 5,76 intravenous immunoglobulin or plasma exchange has been administered in the event of severe or life-threatening attacks, or in children failing to improve with corticosteroid therapy.…”

Section: Current Treatment Recommendationsmentioning

confidence: 99%

Therapies for multiple sclerosis: considerations in the pediatric patient

et al. 2011

View full text Add to dashboard Cite

Current and emerging therapies for multiple sclerosis (MS) offer promise for improved disease control and long-term clinical outcome. To date, these therapies have been evaluated solely in the context of adult MS. However, onset of MS in children is being increasingly recognized, and recent studies have identified a significant impact of MS onset during childhood on cognitive and physical functioning. Optimization of pediatric MS care requires that promising new therapies be made available to children and adolescents, but also that safety and tolerability and potential influence of therapies on the developing immune and neural networks of pediatric patients be closely considered. We propose care algorithms illustrating models for therapy that detail careful monitoring of pediatric patients with MS, provide definitions for inadequate treatment response and treatment escalation, and foster multinational collaboration in future therapeutic trials.

show abstract

“…A clinical trial in Iran showed that monthly administration of 50.000IU vitamin D3 in high schoolchildren significantly increased serum 25(OH) D3 without causing vitamin D toxicity (12). Based on the results of that study we decided to evaluate the effects of monthly 100.000 IU cholecalciferol in the third trimester on serum 25(OH) VitD and iPTH in a group of pregnant Iranian women and their offspring.…”

Section: Introductionmentioning

confidence: 99%

Vitamin D Supplementation in Pregnant Iranian Women: Effects on Maternal and Neonatal Vitamin D and Parathyroid Hormone Status

Sabet¹

2012

Acta Endo (Buc)

View full text Add to dashboard Cite

Context. Vitamin D is essential for skeletal and nonskeletal health and prolonged deficiency results in infantile rickets and adult osteomalacia. The aim of this study is to determine 25(OH) VitD and iPTH status in pregnancy and to evaluate the effects of monthly 100.000 IU dose of vitamin D supplementation.Materials and Methods. In a double blind trial of vitamin D supplementation in pregnant Iranian women, vitamin D3 (cholecalciferol , 100/00 IU/month) was administered to 25 women and placebo to 25 controls during the last trimester. The two groups had similar distributions of maternal age, height, gravity, weight and age of gestation. Hydroxycholcalciferol and iPTH were measured in mothers at 27 weeks and at delivery. Cord blood was used to assess the same parameters.Results. Comparing the data final maternal 25 -hydroxyvitamin D levels were significantly higher in the supplemented group versus control group (61.45±30 ng/mL versus 29.4±16 ng/mL); P ≤ 0.001.Cord 25hydroxyvitamin D levels were significantly higher in supplementation group in comparison to control group (52 ± 40.5 ng/mLversus 36±21.3 ng/mL); P<0.005.Conclusion. Administration of 100/000 IU/monthly of vitamin D3 in the last trimester significantly increased 25(OH) VitD to high normal concentration. However, even with supplementation, only of mother and of newborn had serum 25(OH) VitD greater than 30 ng/mL a small percentage of women and babies were vitamin D sufficient. According to data of study we propose 100/000 IU monthly is safe for pregnant women.

show abstract

Effects of different doses of oral cholecalciferol on serum 25(OH)D, PTH, calcium and bone markers during fall and winter in schoolchildren

Cited by 42 publications

References 39 publications

Vitamin D replacement in children, adolescents and pregnant women in the Middle East and North Africa

Vitamin D replacement in children, adolescents and pregnant women in the Middle East and North Africa

Therapies for multiple sclerosis: considerations in the pediatric patient

Vitamin D Supplementation in Pregnant Iranian Women: Effects on Maternal and Neonatal Vitamin D and Parathyroid Hormone Status

Contact Info

Product

Resources

About